Burkholderia cenocepacia phenotypic clonal variation during a 3.5-year colonization in the lungs of a cystic fibrosis patient

Infection and Immunity

Volumn 79, Issue 7, 2011, Pages 2950-2960

  Coutinho, Carla P ^a   de Carvalho, Carla C C R ^a   Madeira, Andreia ^a   Pinto de Oliveira, Ana ^a   Sá Correia, Isabel ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXOPOLYSACCHARIDE; FATTY ACID; GENTAMICIN; IMIPENEM; MEROPENEM; MYRISTIC ACID; PALMITIC ACID; PALMITOLEIC ACID; TOBRAMYCIN; VACCENIC ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOFILM; BROTH DILUTION; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA INFECTION; CELL MOTILITY; CELL STRUCTURE; CEPACIA SYNDROME; CLONAL VARIATION; CYSTIC FIBROSIS; DEATH; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HYDROPHOBICITY; LIPID COMPOSITION; LUNG FIBROSIS; LUNG FUNCTION; PHENOTYPE; PRIORITY JOURNAL; ZETA POTENTIAL;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA INFECTIONS; CELL MEMBRANE; CYSTIC FIBROSIS; FATTY ACIDS; HUMANS; LUNG; LUNG DISEASES; MEMBRANE LIPIDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 79959405574     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01366-10     Document Type: Article

References (44)

1. Alvarez-Ortega, C., and C. S. Harwood. 2007. Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. Mol. Microbiol. 65:153-165.
2. Baldwin, A., et al. 2005. Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J. Clin. Microbiol. 43:4665-4673.
3. Bernier, S. P., D. T. Nguyen, and P. A. Sokol. 2008. A LysR-type transcriptional regulator in Burkholderia cenocepacia influences colony morphology and virulence. Infect. Immun. 76:38-47.
4. Bevivino, A., et al. 2002. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J. Clin. Microbiol. 40:846-851.
5. Bramer, C. O., P. Vandamme, L. F. da Silva, J. G. C. Gomez, and A. Steinbuchel. 2001. Burkholderia sacchari sp. nov., a polyhydroxyalkanoateaccumulating bacterium isolated from soil of a sugar-cane plantation in Brazil. Int. J. Syst. Evol. Microbiol. 51:1709-1713.
6. Buhler, T., S. Ballestero, M. Desai, and M. R. Brown. 1998. Generation of a reproducible nutrient-depleted biofilm of Escherichia coli and Burkholderia cepacia. J. Appl. Microbiol. 85:457-462.
7. CLSI. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS document M100-S15. CLSI, Wayne, PA.
8. Correia, S., et al. 2008. The clinical course of Burkholderia cepacia complex bacteria respiratory infection in cystic fibrosis patients. Rev. Port. Pneumol. 14:5-26.
9. Cunha, M. V., et al. 2003. Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study. J. Clin. Microbiol. 41:4113-4120.
10. Cunha, M. V., et al. 2007. Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center. J. Clin. Microbiol. 45:1628-1633.
11. Cunha, M. V., et al. 2004. Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections. J. Clin. Microbiol. 42:3052-3058.
12. de Carvalho, C. C. C. R., V. Fatal, S. S. Alves, and M. M. R. da Fonseca. 2007. Adaptation of Rhodococcus erythropolis cells to high concentrations of toluene. Appl. Microbiol. Biotechnol. 76:1423-1430.
13. de Carvalho, C. C. C. R., M. N. Pons, and M. M. R. da Fonseca. 2003. Principal components analysis as a tool to summarise biotransformation data: influence on cells of solvent type and phase ratio. Biocatal. Biotransformation 21:305-314.
14. Drevinek, P., and E. Mahenthiralingam. 2010. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin. Microbiol. Infect. 16:821-830.
15. Dubois, M., K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:350-356.
16. Feliziani, S., et al. 2010. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLos One 5:e12669.
17. Findlay, R. H., G. M. King, and L. Watling. 1989. Efficacy of phospholipid analysis in determining microbial biomass in sediments. Appl. Environ. Microbiol. 55:2888-2893.
18. Geertsema-Doornbusch, G. I., H. C. van der Mei, and H. J. Busscher. 1993. Microbial cell surface hydrophobicity: the involvement of electrostatic interactions in microbial adhesion to hydrocarbons (MATH). J. Microbiol. Methods 18:61-68.
19. Govan, J. R., A. R. Brown, and A. M. Jones. 2007. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2:153-164.
20. Guerzoni, M. E., R. Lanciotti, and P. S. Cocconcelli. 2001. Alteration in cellular fatty acid composition as a response to salt, acid, oxidative and thermal stresses in Lactobacillus helveticus. Microbiology 147:2255-2264.
21. Harrison, F. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology 153:917-923.
22. Herbert, D., P. J. Phipps, and R. E. Stange. 1971. Chemical analysis of microbial cells, vol. 5B. Academic Press, London, United Kingdom.
23. Hoboth, C., et al. 2009. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 200:118-130.
24. Inoue, T., R. Shingaki, and K. Fukui. 2008. Inhibition of swarming motility of Pseudomonas aeruginosa by branched-chain fatty acids. FEMS Microbiol. Lett. 281:81-86.
25. Leitão, J., et al. 2008. Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur. J. Clin. Microbiol. Infect. Dis. 27:1101-1111.
26. LiPuma, J. J., et al. 2001. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 164:92-96.
27. Madeira, A., P. M. Santos, C. P. Coutinho, A. Pinto-de-Oliveira, and I. Sá-Correia. 2010. Quantitative proteomics (2D-DIGE) reveals molecular strategies employed by Burkholderia cenocepacia to adapt to the airways of cystic fibrosis patients under antimicrobial therapy. Proteomics 11:1313-1328.
28. Mahenthiralingam, E., A. Baldwin, and P. Vandamme. 2002. Burkholderia cepacia complex infection in patients with cystic fibrosis. J. Clin. Microbiol. 51:533-538.
29. Marolda, C. L., B. Hauroder, M. A. John, R. Michel, and M. A. Valvano. 1999. Intracellular survival and saprophytic growth of isolates from the Burkholderia cepacia complex in free-living amoebae. Microbiology 145: 1509-1517.
30. McCoy, A. J., H. J. Liu, T. J. Falla, and J. S. Gunn. 2001. Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides. Antimicrob. Agents Chemother. 45:2030-2037.
31. NCCLS. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
32. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253.
33. O'Toole, G. A., and R. Kolter. 1998. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol. Microbiol. 28:449-461.
34. Reid, D. W., G. J. Anderson, and I. L. Lamont. 2009. Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. Am. J. Physiol. Lung C 297:L795-L802.
35. Reid, D. W., V. Carroll, C. O'May, A. Champion, and S. M. Kirov. 2007. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur. Respir. J. 30:286-292.
36. Reik, R., T. Spilker, and J. J. LiPuma. 2005. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J. Clin. Microbiol. 43:2926-2928.
37. Richau, J. A., et al. 2000. Molecular typing and exopolysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic fibrosis center. J. Clin. Microbiol. 38:1651-1655.
38. Rosenberg, M. 1981. Bacterial adherence to polystyrene: a replica method of screening for bacterial hydrophobicity. Appl. Environ. Microbiol. 42:375-377.
39. Schobert, M., and P. Tielen. 2010. Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiol. 5:603-621.
40. Smith, E. E., et al. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103: 8487-8492.
41. Snell, G. I., A. Dehoyos, M. Krajden, T. Winton, and J. R. Maurer. 1993. Pseudomonas-cepacia in lung-transplant recipients with cystic-fibrosis. Chest 103:466-471.
42. Vandamme, P., et al. 1997. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst. Bacteriol. 47:1188-1200.
43. Verstraeten, N., et al. 2008. Living on a surface: swarming and biofilm formation. Trends Microbiol. 16:496-506.
44. Wagner, B. A., G. R. Buettner, and C. P. Burns. 1994. Free radical-mediated lipid-peroxidation in cells-oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry 33:4449-4453.